Instructions / Instruction for use: PhlogenzymI want this, give me price
ATX code L03AX Other immunostimulants
Enzymes and antiferments
Other non-narcotic analgesics, including non-steroidal and other anti-inflammatory drugs
Nosological classification (ICD-10)
B19 Viral hepatitis, unspecified
Anicteric hepatitis, viral hepatitis, Viral hepatitis in children, Infection of the liver, Acute liver infection
G35 Multiple sclerosis
Disseminated sclerosis, multiple sclerosis, Relapsing Multiple Sclerosis, Secondary progressive multiple sclerosis, Exacerbation of multiple sclerosis, Mixed forms of multiple sclerosis
I20 Angina [cardiac angina]
heberden disease, Angina pectoris, The attack of angina pectoris, recurrent angina, Spontaneous angina, Stable angina pectoris, angina, Angina (attack), Angina rest, Angina progressing, Angina mixed, Angina spontaneous, sable angina, Chronic stable angina, Angina Syndrome X
I22 Recurrent myocardial infarction
Atherosclerosis and the likelihood of recurrent myocardial infarction, Myocardial infarction repeated, Relapses of myocardial infarction
I25.9 Chronic ischemic heart disease, unspecified
CHD, Insufficiency of coronary circulation, Coronary atherosclerosis in patients with ischemic heart disease
I63 Cerebral infarction
Stroke ischemic, Ischemic disease of the brain, Ischemic stroke, Ischemic stroke and its consequences, Ischemic cerebral stroke, Ischemic impairment of cerebral circulation, Ischemic damage of the brain, Ischemic brain damage, Ischemic state, Ischemia of the brain, Acute hypoxia of the brain, Acute cerebral ischemia, Acute ischemic impairment of cerebral circulation, Acute cerebral infarction, Acute ischemic stroke, Acute period of ischemic stroke, Focal cerebral ischemia, Postponed ischemic stroke, Repeated stroke, Morgagni-Adams-Stokes Syndrome, Chronic cerebral ischemia, Cerebrovascular stroke, Embolic Stroke, Ischemic brain damage
I70.2 Atherosclerosis of the arteries of the extremities
Arteriosclerosis obliterans, Arteriosclerosis of peripheral arteries, Atherosclerosis of lower limb arteries, Atherosclerosis of peripheral arteries, Atherosclerosis of the vessels of the extremities, Obliterating disease of lower extremities, Obliterating atherosclerosis, Obliterating arteriosclerosis of lower limb arteries, Obliterating arteriosclerosis of the vessels of the upper limbs, Obliterating atherosclerosis of vessels of lower extremities, Atherosclerosis of the arteries of the extremities,Arteriopathy of the extremities, Obliterating atherosclerosis of the vessels of the extremities, Obliterating arteriosclerosis
I74 Embolism and arterial thrombosis
Thrombosis of effort (tension), Arterial thrombosis, Arteriothrombosis, Subacute and chronic arterial thrombosis, Subacute thrombosis of peripheral arteries, Postoperative thrombosis, Vascular thrombosis, Vascular embolism, Thrombosis of aortocoronary shunt, Arterial thrombosis, Thrombosis of arteries, Coronary artery thrombosis, Coronary thrombosis, Thrombosis of blood vessels, Thrombosis with ischemic stroke, Thrombosis with general surgical operations, Thrombosis in Oncology Operations, Vascular thrombosis, Thrombus formation in the postoperative period, Thrombotic complications. Thromboembolic diseases, Thromboembolic complications, Thromboembolic syndrome, Thromboembolic complication, Thromboembolic complication in the postoperative period, Thromboembolism of arteries, Partial vascular thrombosis, Embolism, Embolism of arteries
I79.8 Other disorders of arteries, arterioles and capillaries in diseases classified elsewhere
Atherosclerotic occlusive lesions of peripheral arteries, Disorders of microcirculation, Disorders of microcirculation, Obstruction in the system of coronary circulation
I80.0 Phlebitis and thrombophlebitis of superficial vessels of lower extremities
Thrombophlebitis of superficial veins, Thrombophlebitis of superficial veins of legs, Thrombophlebitis of superficial veins, Phlebitis of superficial veins of legs, Inflammation of veins
I87.0 Postphlebitic syndrome
Postthrombotic venous insufficiency, Postthrombotic disease, Post thrombophlebitic syndrome, Post-thrombophlebitis, Post-thrombophlebitic syndrome, Postphlebitic syndrome, Post thrombotic syndrome, Postphlebitis Syndrome, Postphlebitic syndrome (stasis syndrome)
I89.0 Lymphocyte, not elsewhere classified
Venous-lymphatic insufficiency, Lymphatic edema, Lymphedema, Lymphostasis, Lymphostasis and swelling after treatment of breast cancer, Edema lymphangiectatic, Lymphatic edema, Chronic lymphostasis, Lymphodema
J18 Pneumonia without specifying the pathogen
Alveolar pneumonia, Community-acquired pneumonia is atypical, Community-acquired pneumonia nepnevmokokkovaya, Pneumonia, Inflammation of the lower respiratory tract, Inflammatory disease of the lungs, lobar pneumonia, Infections of the respiratory tract and lungs, Infections of the lower respiratory tract, Cough in inflammatory diseases of the lung and bronchus, lobar pneumonia, nosocomial pneumonia, Exacerbation of chronic pneumonia, Acute community-acquired pneumonia, Acute pneumonia, lobular pneumonia, Pneumonia abscessed, bacterial Pneumonia, lobar pneumonia, Pneumonia alopecia, Pneumonia with obstruction of sputum discharge, Pneumonia in AIDS patients, Pneumonia in Children, Septic pneumonia, Chronic obstructive pneumonia, Chronic pneumonia, Lymphoid interstitial pneumonia
J44 Other chronic obstructive pulmonary disease
Allergic bronchitis, Bronchitis asthma, Asthmatic bronchitis, wheeze bronchitis, Bronchitis is an obstructive, bronchi disease, Shortness of sputum in acute and chronic respiratory diseases, Cough in inflammatory diseases of the lung and bronchus, Reversible airflow obstruction, Reversible obstructive airway disease, Obstructive bronchitis disease, Obstructive lung disease, Obstructive bronchitis, Spastic bronchitis, Chronic lung disease, Chronic nonspecific lung diseases, Chronic obstructive pulmonary disease, Chronic obstructive bronchitis, Chronic obstructive airway disease, Chronic obstructive pulmonary disease, Restrictive lung pathology
K10.2 Inflammatory diseases of the jaws
Infections of maxillofacial area, Purulent-inflammatory processes of maxillofacial area
K76.9 Liver disease, unspecified
Change in liver function in heart failure, Restoration of impaired liver function, Severe liver function disorders, Hepatitis, Hepatosis, Hepatopathy, Liver dysfunction, Diseases of the liver, Impaired liver function, Dysfunction of the liver, Infringements of function of a liver of an inflammatory etiology, Functional liver failure, Functional disorders of the liver, Chronic liver disease, Chronic diffuse liver disease, Enterogenic diseases of the gallbladder and liver
L91.0 Keloid cicatrix
Hyperlusculation, Keloid, Keloid cicatrix, Kelloid scars
M02 Reactive arthropathy
M35.3 Rheumatic polymyalgia
Pseudoarthritis rhizomelic, Rheumatic polymyalgia, Pain syndrome in rheumatic diseases, Muscle pain with rheumatism, Extra-articular rheumatism, Extra-articular rheumatic syndrome, Extra-articular rheumatic diseases, Extra-articular rheumatic soft tissue injury, Extra-articular forms of rheumatism, Rheumatic soft tissue damage, Rheumatism of soft tissues, Rheumatic diseases of soft tissues, Rheumatic diseases of the periarticular soft tissues, Rheumatic affections of soft tissues, Rheumatic collagen diseases
M45 Ankylosing spondylitis
Ankylosing spondylarthrosis, Marie-Strumpel disease, Ankylosing spondylitis, Pain syndrome in acute inflammatory diseases of the musculoskeletal system, Pain syndrome in chronic inflammatory diseases of the musculoskeletal system, Bechterew's disease, Ankylosing spondylitis, Diseases of the spinal column, Rheumatic spondylitis, Bechterew-Marie-Strumpel disease
N30.9 Cystitis, unspecified
Cystitis complicating tumors of the urinary bladder
N34 Urethritis and urethral syndrome
Buzhirovanie urethra, Gonococcal urethritis, Urethrocystitis, Gonorrheic urethritis, Urethritis, Non-gonococcal urethritis, Negative urethritis, Lesion of the urethra, Acute gonococcal urethritis, Acute gonorrhea urethritis, Acute urethritis, Infection of the urethra, Bacterial nonspecific urethritis, Bacterial urethritis
N39.0 Urinary tract infection without established localization
Fungal infections of the urinary tract, Asymptomatic bacteriuria, Bacterial infections of the urinary tract, Bacterial infections of the genitourinary system, Bacteriuria, Bacteriuria asymptomatic, Bacteriuria chronic latent,Asymptomatic bacteriuria, Asymptomatic massive bacteriuria,Inflammatory urinary tract disease, Inflammatory urinary tract disease,Inflammatory diseases of the bladder and urinary tract, Inflammatory diseases of the urinary system, Inflammatory diseases of the urinary tract, Inflammatory diseases of the urogenital system, Fungal diseases of the urogenital tract, Urinary Tract Infections,Urinary Tract Infections, Infections of the urinary system, Urinary tract infections, Urinary Tract Infections, Urinary tract infections caused by enterococci or mixed flora, Urinary tract infections uncomplicated, Urinary tract infections complicated, Infections of the urogenital system, Infections urogenital, Infectious diseases of the urinary tract, Urinary Tract Infection, Urinary tract infection, Urinary system infection, Urinary tract infection, Urinary tract infection,Infection of the urogenital tract, Uncomplicated urinary tract infections, Uncomplicated infections of the genitourinary system, Exacerbation of chronic urinary tract infection, Retrograde kidney infection, Recurrent urinary tract infections, Recurrent urinary tract infections,Recurrent infectious diseases of the urinary tract, Mixed urethral infections, Urogenital infection, Urogenital Infectious-Inflammatory Disease, Urogenital mycoplasmosis, Urologic disease of infectious etiology, Chronic urinary tract infection, Chronic inflammatory diseases of the pelvic organs, Chronic urinary tract infections, Chronic infectious diseases of the urinary system
N41.9 Inflammatory disease of prostate, unspecified
N70 Salpingitis and oophoritis
Adnexitis, Inflammatory diseases of female genitalia, Inflammatory diseases of female genital organs, Infection of the genitals, Oophoritis, Acute adnexitis, Salpingitis, Salpingo-oophoritis, Chronic inflammatory diseases of the ovaries, Inflammation of the ovaries
N95.1 menopausal and menopausal status of women
Atrophy of the mucosa of the lower genital tract, caused by estrogen deficiency; Vaginal dryness; Autonomic dysfunction in women; gipoestrogeniya state; Deficiency of estrogen in menopausal women; Degenerative changes of the mucous membrane in the menopause; Natural menopause; an intact uterus; climacteric; Menopause women; Menopause in women; menopausal depression; Climacteric ovarian dysfunction; Menopause; Climacteric neurosis; Menopause; Menopausal symptoms complicated psychovegetative; Climacteric syndrome; Climacteric vegetative disorders; Climacteric psychosomatic disorder; menopausal disorders; Menopausal disorders in women; menopausal condition; Climacteric vascular disorders; Menopause; Menopausal vasomotor symptoms; menopausal period; Lack of estrogen; Feeling the heat; Pathological menopause; perimenopause; menopause; postmenopausal; Premature menopause; premenopauznom period; tides; hot flashes; flushing in the Meno and postmenopausal; Hot flashes / hot flashes in menopause; Heart attack during menopause; Early menopause in women; Disorders of menopause; climacteric syndrome; Vascular complications of menopause; Physiological menopause; Estrogendefitsitnye state; premature Menopause
N99.4 Postoperative adhesions in the pelvis
T02.9 Multiple fractures, unspecified
Fracture of bones
T14.9 Injury unspecified
Pain syndrome after trauma, Pain syndrome with injuries, Pain syndrome with trauma and after surgery, Pain in case of injury, Pain of a traumatic nature, Joint pain with injuries, Postoperative and post-traumatic pain, Pain in case of injury, Pain of a traumatic origin, Severe pain syndrome of traumatic origin, Deep tissue damage, Deep scratches on the trunk, Closed injury, Minor Household Injuries, Minor skin damage, Violations of the integrity of soft tissues, Uncomplicated trauma, Extensive traumatic injury, Acute pain syndrome of traumatic origin, Edema with trauma, Postponed sports injuries, Post-traumatic pain, Soft tissue injuries, Joint wounds, Sports injuries, Injury, Traumatic pain, Traumatic pains, Traumatic infiltrate,Injuries to sports
T30 Thermal and chemical burns, unspecified
Pain syndrome with burns, Pain in burns, Pain with burns, Sluggishly healing post-burn wounds, Deep burns with a wet scab, Deep burns with abundant compartments, Deep burn, Laser burn, Burn, Burning of the rectum and perineum, Burn with mild exudation, Burn disease, Burn injury, Superficial burn, Superficial burn of I and II degree, Superficial skin burns, After-burn trophic ulcer and wound, Post-burn complication, Loss of fluid during burns, Sepsis burn, Thermal burns, Thermal skin lesions, Thermal burn, Trophic after-burn ulcers, Chemical burn, Surgical burn
T79.3 Post-traumatic wound infection, not elsewhere classified
Inflammation after surgery and trauma, Inflammation after trauma, Secondary infection of skin and mucous membrane damage, Deep Wounds, Purulent wound, Purulent necrotic phase of wound process, Purulent-septic diseases, Purulent wounds, Purulent wounds with the presence of deep cavities, Granulating wounds of small size, Disinfection of purulent wounds, Wound Infections, Infections wound, Infection of wounds, Infected and non-healing wound, Infected postoperative wound, Infected wound, Infected Skin Wounds, Infected burns, Infected Wounds, Suppurating postoperative wounds, Extensive purulent-necrotic process of soft tissues, Burn infections, Burn infection, Perioperative infection, Poorly healing infected wound, Postoperative and purulent-septic wound, Postoperative wound infection, Wound infection, Wound botulism, Wound infections, Wounds of purulent, Wounds infected, Reinfection of granulating wounds, Sepsis posttraumatic
T84.5 Infection and inflammatory response due to endoprosthetics
Z100 * CLASS XXII Surgical practice
Abdominal surgery, adenomectomy, Amputation, Coronary angioplasty, Angioplasty of the carotid arteries, Antiseptic skin treatment for wounds, Antiseptic Hand, Appendectomy, atherectomy, Balloon coronary angioplasty, Vaginal hysterectomy, The coronary bypass, Interventions in the vagina and cervix, Interventions on the bladder, Intervention in the mouth, Restoration and reconstructive surgery, Hand hygiene of medical personnel, Gynecologic surgery, Gynecological intervention, Gynecological surgery, Hypovolemic shock during operations, Disinfection of purulent wounds, Disinfection of wounds edges, Diagnostic intervention, Diagnostic procedures, Cervical Diathermocoagulation, Long-surgery, Replacing the fistula catheters, Infection in orthopedic surgery, Artificial heart valve, cystectomy, Short-term outpatient surgery, Short-term operation, Short surgical procedures, Krikotireotomiya, Blood loss during surgery, Bleeding during surgery and in the postoperative period, Kuldotsentez, laser photocoagulation, laser coagulation, retinal laser coagulation, Laparoscopy, Laparoscopy in Gynecology, CSF fistula, Small gynecological operations, Small surgical procedures, Mastectomy and subsequent plastic, mediastinotomy, Microsurgical operations on the ear, Mukogingivalnye operation, suturing, Minor surgery, neurosurgical operation, Immobilization of the eyeball in ophthalmic surgery, testectomy, pancreatectomy, Perikardektomiya, The period of rehabilitation after surgery, The period of, convalescence after surgery, Percutaneous transluminal coronary angioplasty, Pleural thoracentesis, Pneumonia postoperative and posttraumatic, Preparation for surgical procedures, Preparation for surgery, Preparation of the surgeon's hands before surgery, Preparation of the colon for surgical procedures, Postoperative aspiration pneumonia in neurosurgical and thoracic surgery, Postoperative nausea, Postoperative bleeding, postoperative granuloma, postoperative shock, The early postoperative period, myocardial revascularization, Radiectomy, gastric Resection, bowel resection, uterine Resection, liver Resection, enterectomy, Resection of part of the stomach, Reocclusion of the operated vessel, Bonding tissues during surgical procedures, Removal of sutures, Condition after eye surgery, Condition after surgery, Condition after surgery in the nasal cavity, Condition after gastrectomy, Status after resection of the small intestine, Condition after tonsillectomy, Condition after removal of the duodenum, Condition after phlebectomy, Vascular surgery, Splenectomy, Sterilization of surgical instruments, Sterilization of surgical instruments, sternotomy, Dental surgery, Dental intervention in periodontal tissues, strumectomy, Tonsillectomy, Thoracic surgery, total gastrectomy, Transdermal intravascular coronary angioplasty, Transurethral resection, Turbinektomiya, Removal of a tooth, cataract surgery, Removal of cysts, tonsillectomy, Removal of fibroids, Removing the mobile primary teeth, Removing polyps, Removing broken tooth, Removal of the uterus body, Removal of sutures, Urethrotomy, Fistula likvoroprovodyaschih ways, Frontoetmoidogaymorotomiya, Surgical infection, Surgical treatment of chronic limb ulcersm, Surgery, The surgery in the anal area, The surgery on the colon, Surgical practice, The surgical procedure, Surgical interventions, Surgery on the gastrointestinal tract, Surgical procedures on the urinary tract, Surgical procedures on the urinary system, Surgical intervention of the genitourinary system, Surgical procedures on the heart, Surgical manipulation, surgery, Surgery on the veins, Surgical intervention, Vascular surgery, Surgical treatment of thrombosis, cholecystectomy, Partial gastric resection, transabdominal hysterectomy, Percutaneous transluminal coronary angioplasty, Percutaneous transluminal angioplasty, Coronary artery bypass, tooth Extirpation, Extirpation of milk teeth, pulpectomy, pulsative cardiopulmonary bypass, tooth Extraction, teeth Extraction, cataract extraction, Electrocoagulation, endourological intervention, episiotomy, Etmoidotomiya, Complications after tooth extraction
Z54.0 recovery period after surgery
Conditions after brain surgery, Status after removal of gallstones, Conditions after surgery, The recovery period after surgery, The period of convalescence after surgery, The rehabilitation period after surgery, The period of rehabilitation after surgery, The period of convalescence after surgery, The period of convalescence after surgery, Convalescence in the postoperative period, The period of recovery after surgery on the eyes, The period after hemorrhoidectomy, The period after the surgery, The period of postoperative rehabilitation, The period of rehabilitation after injury
Z96.5 Presence of implants of the roots of teeth and jaw
Implantation of artificial dental roots
Z96.7 Presence of implants of other bones and tendons
Tablets, covered with an enteric coating.
bromelain 450 units (FIP)
trypsin 1440 units (FIP) (24 μkat)
rutin (rutozide) 100 mg
auxiliary substances: lactose monohydrate - 148.58 mg; cornstarch - 24 mg; magnesium stearate - 12.72 mg; stearic acid - 11.28 mg; purified water - 6.6 mg; silicon dioxide colloidal - 6.36 mg; talc - 2.46 mg
shell: methacrylic acid and methyl methacrylate copolymer (1: 1) - 11.89 mg; macrogol 6000 - 0.67 mg; talc - 4.08 mg; triethyl citrate 1.2 mg; vanillin - 0.15 mg
Description of dosage form
The biconvex tablets are round in shape, coated with a smooth surface of a greenish-yellow color, a characteristic odor; minor deviations from homogeneity of color are admissible: marble pattern, dot blotches.
The core of the tablet on the cross-section of light yellow color, tuberous, the shell - light yellow color.
Pharmacological action - anti-inflammatory, immunomodulating.
Phlogenzym is a new generation medicinal product consisting of a combination of highly active proteolytic enzymes (enzymes) of plant and animal origin, bromelain and trypsin in combination with routine. In combination, the enzymes exert a pleiotropic (multiple) effect, having a variety of pharmacological actions on pathophysiological and biochemical processes. Enzymes of the drug realize their therapeutic effects through anti-inflammatory, immunomodulating, antiaggregant, fibrinolytic, thrombolytic, decongestant and secondary analgesic actions. The tablets of the drug, coated with an enteric coating, transitively pass the upper sections of the gastrointestinal tract, not injuring the stomach, are absorbed in the small intestine by resorption of intact molecules (endocytosis, pinocytosis). Proteases of the drug, binding to blood transport proteins (α-2-macroglobulin and α-1-antitrypsin) form a reversible protease-antiprotease complex in which the antigenic determinants of exogenous proteases of the preparation are masked, which prevents allergic reactions. As a result of formation of a complex with enzymes, antiprotease (α-2-macroglobulin) passes into the active form, which serves as an extracellular regulator of pro-inflammatory cytokines and growth factors, carrying out their transfer, clearance and elimination.
The formation of an active protease-antiprotease complex allows the proteolytic enzymes to be safely moved along the vascular bed to the site of inflammation and to the site of injury, regardless of the site of localization in the body. The complex keeps and slows the removal of proteolytic enzymes of the drug from the body, increases the time of their circulation in the vascular bed and, accordingly, the therapeutic effect. Getting into the inflammatory focus and wounds, proteolytic enzymes break down (hydrolyse) damaged proteins, tissues and eliminate (remove) cellular debris (detritus), contributing to the acceleration of the cleansing and healing of the wound.
The drug positively affects the course of the inflammatory process, modulates the protective reactions of the body, which contributes to the physiological course of inflammation at different stages. Proteolytic enzymes of the drug accelerate the disintegration of inflammatory mediators, cleave immune complexes and membrane deposits, increase the activity of phagocytes, natural killer cells, stimulate interferonogenesis. Proteases of the drug reduce the level of proinflammatory cytokines (IL-1β, IL-6, IL-8, INF-γ, TNF-α) and promote the production of anti-inflammatory cytokines (including IL-4, IL-10), regulate the level Ig and antibodies of blood. Enzymes of the drug limit the pathological manifestations of autoimmune and immunocomplex processes, restore the immunological reactivity of the organism.
Protease drugs reduce the level of transforming growth factor β, the increase of which leads to excessive scarring. Proteolytic enzymes have a regulatory effect on the synchronization of the formation of the basement membrane (laminin), the modulation of the wound process and the expression of angiogenesis factors (vasculoendothelial growth factor, fibroblast growth factor and a number of other factors). Thus, the enzymes of the drug contribute to the improvement of reparative processes, the prevention of the formation of hypertrophic and keloid scars, the development of adhesions after surgical interventions on the abdominal cavity.
Enzymes of the drug positively affect the improvement of microcirculation, increase the delivery of oxygen and nutrients to the wound, reduce inflammation in the lesion, maintain the physiological process of regeneration and accelerate the restoration of the function of organs and tissues.
The drug improves the rheological properties of blood (viscosity and fluidity) due to the positive effect on the functional state of blood cells and the vascular wall, plasticity (deformability) of erythrocytes, stabilization of the permeability of the endothelium, increased fibrinolytic activity of blood serum, a decrease in the density of adhesive molecules, reduced platelet aggregation .
Proteolytic enzymes reduce the number of activated forms of platelets (spheroehinocytes) and micro- and macroaggregates; reducing the risk of blood clots in the vessels, and simultaneously participate in the lysis of the formed blood clots. Proteolytic enzymes reduce the level of atherogenic lipids, promoting increased HDL, reducing the risk of atherosclerosis and vascular disorders.
The drug improves the blood supply to the bronchi and lung tissue in chronic respiratory diseases, incl. caused by smoking, improves the viscosity properties of bronchial secretion, the function of ciliated epithelium, restores the drainage function of the bronchi, dilutes sputum, which facilitates breathing and reduces cough.
Proteolytic enzymes of the drug increase the effectiveness of antibiotics while reducing unwanted effects of antibiotic therapy (dysbiosis, irritable bowel syndrome). Proteases improve the cleavage of substrates, optimize the balance of microbiota, promote the restoration of endoecology of the intestine.
In complex therapy and prevention of the following diseases and conditions:
surgery - postoperative recovery and rehabilitation of patients (improvement of reparative processes and regeneration), postoperative purulent-inflammatory complications, prevention of adhesions and keloid scar formation, reduction of the risk of thromboembolic complications during prolonged immobilization;
Traumatology - fractures of bones, injuries of tendons and ligaments, bruises and bruises of soft tissues, sports injuries, burns, better integration of endoprostheses, osteosynthesis;
angiology - acute deep vein thrombosis, superficial vein thrombophlebitis, postthrombotic disease, obliterating atherosclerosis of lower extremity arteries and other chronic angiopathies, microcirculatory disorders, lymphatic edema (lymphedema);
urology - acute and chronic inflammation of the urinary tract (cystitis, urethritis, cystopyelitis, prostatitis);
gynecology - acute and chronic inflammatory diseases of the pelvic organs (adnexitis, salpingoophoritis), vascular complications of the climacteric period, a decrease in the frequency and severity of complications of hormone replacement therapy;
cardiology - IHD, prevention of angina attacks, reduction of the risk of vascular accidents and repeated heart attacks;
gastroenterology - hepatitis;
rheumatology - rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, rheumatic soft tissue damage;
neurology - ischemic stroke, multiple sclerosis;
pulmonology - pneumonia, chronic obstructive pulmonary disease;
dentistry - prevention of complications in the postoperative period during extraction of teeth, purulent-inflammatory diseases of the maxillofacial area, rehabilitation and recovery after surgical interventions on the maxillofacial area, improvement of implant integration, osteosynthesis.
individual intolerance to the components of the drug;
congenital or acquired coagulation disorders;
With caution: conducting hemodialysis (after consulting a doctor).
pregnancy and lactation
Take the drug with caution after consulting a doctor.
The drug is well tolerated by patients. In some cases, there may be more frequent stools, a change in the consistency and odor of the stool, which quickly stop when the dosage of the drug is temporarily reduced. Occasionally, an allergic reaction may occur (skin rash, itching), which disappears after a dose reduction or drug withdrawal. If the conditions of application of the drug are violated, nausea, swelling and pain in the abdomen, headache, dizziness, exanthema, general weakness, sensation of fullness of the intestine may occur. These conditions disappear after a decrease in dosage or a temporary discontinuation of the drug.
There were no incidents of incompatibility with other drugs. The use of the drug together with antibiotics increases the effectiveness of antibiotic therapy. When used with hormones, the drug reduces the risk of thrombosis.
Dosing and Administration
Take at least 30 minutes before eating, without cracking, washing with water (200 ml). After the operation, the drug should be taken from the 2nd-3rd day.
Treatment. The drug is taken after trauma and surgery or acute inflammation for the cleavage and removal of damaged tissues, resorption of hematomas, improvement of trophic tissue and repair processes, reducing inflammation and edema, reducing the risk of complications - thrombosis, development of adhesive disease, keloid scar formation and wound suppuration: 3 Table. 3 times a day for 2 weeks. If necessary, to improve recovery and healing, the course of taking the drug can be prolonged up to 4 weeks or more for 2 tablets. 3 times a day.
Prevention of complications. To prevent long-term consequences after surgery - thromboembolic complications, development of adhesive disease of the abdominal cavity, trophic disorders during prolonged bed rest and immobilization of the patient: the drug is recommended to take a long course in a dosage of 2 tablets. 3 times a day for 4 weeks or more or for the entire period of immobilization.
Use with antibiotics. When prescribing antibiotics, the drug is used to increase the effectiveness of antibiotic therapy and to reduce the undesirable effects of antibiotics. The drug is recommended to be taken throughout the course of antibiotic therapy according to 2 tablets. 3 times a day.
Use with hormones. When appointing long courses of hormones, the drug is recommended to reduce the risk of complications (thrombosis) by 2 tablets. 3 times a day during the entire course of taking hormonal drugs. When prescribing hormone replacement therapy to reduce the risk of venous thrombosis of the lower extremities, the drug is recommended to take 2 tablets. 3 times a day by repeated courses for 2 weeks with breaks of 3 weeks 3-4 times a year.
Prevention. To prevent thrombosis of the veins of the lower extremities and reduce the risk of vascular accidents (infarction), the drug is recommended to take 2 tablets. 3 times a day for at least 3-4 weeks, repeating the course of taking the drug 3-4 times a year.
Changing the course and dosages of the drug is recommended after consulting a doctor.
Cases of drug overdose are unknown.
In the case of infectious processes, FGLENZIM does not replace antibiotics.
In case of an exacerbation of the underlying disease, when taking the drug, a temporary reduction in the dose of the drug or temporary withdrawal of the drug after consultation with a doctor is recommended.
Patients suffering from diabetes should note that each tablet contains 0.015 XE.
Influence on the ability to drive a car or perform work that requires an increased speed of physical and mental reactions. The drug is not doping, does not have a negative impact on driving and performance of work requiring a high rate of mental and physical reactions.
Form of issue
Tablets coated with enteric coating: in PVC blisters / aluminum foil of 20 pcs .; in vials of LDPE for 800 pcs .; in a pack of cardboard 2, 5 or 10 blisters.
Conditions of leave from pharmacies
In a dry place, at a temperature of 15-25 ° C.
Keep out of the reach of children.
Do not use after the expiry date printed on the package.